The chemoresistance that occurs within lung cancer cells may be mediated by the stress response of CCL2‐expressing cells, implicating CCL2 as a possible target for augmenting the therapeutic efficacy of DTX on lung cancer.117. This evidence concerns the gene CCL2 and lung cancer.